Combination of IAP Inhibitor and Immune Checkpoint Inhibitor
Summary
The European Patent Office published patent EP3936126A1 granted to Chia Tai Tianqing Pharmaceutical Group Co., Ltd. covering a combination therapy using IAP (Inhibitor of Apoptosis Proteins) inhibitors with immune checkpoint inhibitors for treating cancer. The patent designates all EPC contracting states across Europe.
What changed
EPO granted patent EP3936126A1 to Chia Tai Tianqing Pharmaceutical Group Co., Ltd. for a therapeutic combination comprising an IAP inhibitor with an immune checkpoint inhibitor for cancer treatment. The patent covers compositions and methods using specific IAP inhibitor compounds (A61K 31/4045, C07D 403/06) in combination with checkpoint inhibitors for treating malignancies (A61P 35/00).
Pharmaceutical companies developing cancer immunotherapies should be aware of this patent portfolio, particularly those operating in designated EPC states (DE, FR, GB, IT, ES, NL, and others). Freedom-to-operate analyses for combination cancer therapies may need to account for this patent when considering IAP inhibitor/checkpoint inhibitor combinations.
What to do next
- Monitor for updates
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR
Publication EP3936126A1 Kind: A1 Apr 01, 2026
Applicants
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
Inventors
LIU, Yingchun, XU, Zhaobing, HAN, Shuhua, HU, Lihong, DING, Charles Z., XIA, Yuanfeng, TONG, Haijun, HE, Lihua, TIAN, Xin
IPC Classifications
A61K 31/4045 20060101AFI20260220BHEP A61P 35/00 20060101ALI20260220BHEP C07D 403/06 20060101ALI20260220BHEP A61K 31/4178 20060101ALI20260220BHEP A61K 31/422 20060101ALI20260220BHEP A61K 31/404 20060101ALI20260220BHEP A61K 31/4155 20060101ALI20260220BHEP A61K 31/416 20060101ALI20260220BHEP A61K 45/06 20060101ALI20260220BHEP C07D 403/14 20060101ALI20260220BHEP C07D 413/14 20060101ALI20260220BHEP C07D 471/04 20060101ALI20260220BHEP A61K 39/395 20060101ALI20260220BHEP C07K 16/28 20060101ALI20260220BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.